A 28-year-old woman presents with photosensitive malar rash, arthralgia of small joints, and oral ulcers for 3 months. Laboratory findings show ANA positivity (1:640, homogeneous pattern) and low complement levels (C3 and C4). Which investigation is most specific for confirming the diagnosis of SLE?

Explanation

## Diagnosis Confirmation in SLE **Key Point:** Anti-dsDNA and anti-Sm antibodies are highly specific for SLE and are part of the ACR/EULAR classification criteria. ### Why Anti-dsDNA and Anti-Sm? **High-Yield:** Anti-Sm antibodies are 99% specific for SLE (though only 20–30% sensitive), making them the most specific single test. Anti-dsDNA antibodies are present in 60–70% of SLE patients and correlate with lupus nephritis activity. | Antibody | Sensitivity | Specificity | Clinical Significance | | --- | --- | --- | --- | | Anti-Sm | 20–30% | 99% | Highly specific; part of SLE criteria | | Anti-dsDNA | 60–70% | 95% | Correlates with nephritis; prognostic value | | ANA | 95–98% | 70–80% | Sensitive but not specific | | Anti-Ro/SSA | 40–60% | 90% | Associated with photosensitivity | **Clinical Pearl:** The combination of ANA positivity (homogeneous pattern), low complement (C3/C4), and clinical features (malar rash, arthralgia, oral ulcers) strongly suggests SLE. Anti-dsDNA and anti-Sm antibodies confirm the diagnosis and help distinguish SLE from other autoimmune conditions. ### Diagnostic Algorithm ```mermaid flowchart TD A[Clinical suspicion of SLE]:::outcome --> B[ANA screening]:::action B --> C{ANA positive?}:::decision C -->|Yes| D[Check anti-dsDNA and anti-Sm]:::action C -->|No| E[SLE unlikely]:::outcome D --> F{Anti-Sm or anti-dsDNA positive?}:::decision F -->|Yes| G[SLE confirmed]:::outcome F -->|No| H[Consider other autoimmune disease]:::outcome D --> I[Check complement C3, C4]:::action I --> J[Low complement = active disease]:::outcome ``` **Mnemonic:** **SLAM** criteria include **S**mith antibodies (anti-Sm) — the most specific marker for SLE diagnosis.